Evidence map›Paper›PMID 42562811›Full record

ArticleBlood cancer journal2026

Post-transplant hypomethylating agents plus venetoclax maintenance improves survival in high-risk myeloid malignancies: A matched cohort study.

Haley Thigpen, Kendall Diebold, Todd Mudd, Maris Hardee, Manuel Espinoza-Gutarra, Antonio Di Stasi, Donna Salzman, Razan Mohty, Jorge Cortes, Ravi Bhatia and 1 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Haley ThigpenDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Kendall DieboldDivision of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Todd MuddDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID http://orcid.org/0009-0001-2300-4499
Maris HardeeDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Manuel Espinoza-GutarraDivision of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Antonio Di StasiDivision of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Donna SalzmanDivision of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Razan MohtyDivision of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Jorge CortesDivision of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Ravi BhatiaDivision of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID http://orcid.org/0000-0001-5740-2316
Omer JamyDivision of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. omerjamy@uabmc.edu.ORCID http://orcid.org/0000-0003-2411-4742

Funding

STIMULATING ACCESS TO INFECTIOUS DISEASES RESEARCH IN RESIDENCY (UAB StARR)R38AI174267 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WILLIAM M GEISLER · 2024 to 2026
$969k
NIAID NIH HHS R38 AI174267
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42562811
PMCPMC13448468

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.